Pharmaceuticals are slow in the take - up of digital technology , concluded a panel discussion at MedCity CONVERGE . The industry is " generations " behind clinics in the use of AI , said Tom Kottler , CEO of HealthPrize Technologies , noting Roche 's $ 1.9bn acquisition of Flatiron Healthcare as a sign that things are changing . Some drug companies are already embracing digital therapeutics. Furthermore , Novartis partnered with Pear Therapeutics for digital solutions to supplement its drugs for depression and multiple sclerosis . Roche cited depression and addiction as areas in which AI could me more beneficial than drugs . Meanwhile , AI could help prevent the rising cost of drugs , said Derek Bowen from Blackfynn .
Pharmaceuticals are slow in the take - up of digital technology , concluded a panel discussion at MedCity CONVERGE . The industry is " generations " behind clinics in the use of AI , said Tom Kottler , CEO of HealthPrize Technologies , noting Roche 's $ 1.9bn acquisition of Flatiron Healthcare as a sign that things are changing . Furthermore , Novartis partnered with Pear Therapeutics for digital solutions to supplement its drugs for depression and multiple sclerosis . Roche cited depression and addiction as areas in which AI could me more beneficial than drugs . Meanwhile , AI could help prevent the rising cost of drugs , said Derek Bowen from Blackfynn .